title: Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
abstract: BACKGROUND
  Rotavirus disease causes a significant health and economic burden worldwide. Several rotavirus vaccines may soon be available for use. A country's decision to introduce these vaccines will depend on its rotavirus disease burden, on the cost of the vaccine, and on the results of an economic assessment of the cost and effectiveness of a rotavirus vaccination program.
  
  
  METHODS
  Data on medical and nonmedical direct costs and indirect costs were established in Khanh Hoa Province, Vietnam, and extrapolated to national estimates on the basis of the birth cohort in 2004. The main outcome measures were economic burden and cost-effectiveness ratio (United States dollars per disability-adjusted life-year averted and dollars per life saved) of vaccination.
  
  
  RESULTS
  The disease burden is equivalent to an economic burden of an estimated 3.1 million US dollars in medical direct costs, 685,000 US dollars in nonmedical direct costs, and 1.5 million US dollars in indirect costs. From a societal perspective, treatment of rotavirus disease costs an estimated 5.3 million US dollars per year. From the health care system perspective, universal vaccination of infants at a cost of < or = 7.26 US dollars/vaccine dose would be a cost-effective public health intervention, according to the World Bank cost-effectiveness standard for low-income countries (140 US dollars/disability-adjusted life-year).
  
  
  CONCLUSIONS
  Vaccination can effectively reduce the disease burden and health care costs of rotavirus-specific diarrhea in Vietnam.
authors.affiliation: Division of Viral and Rickettsial Diseases and Epidemiology Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Thea K
authors.initials: TK
authors.lastname: Fischer
authors.forename: Dang Duc
authors.initials: DD
authors.lastname: Anh
authors.forename: Lynn
authors.initials: L
authors.lastname: Antil
authors.forename: N D L
authors.initials: ND
authors.lastname: Cat
authors.forename: Paul E
authors.initials: PE
authors.lastname: Kilgore
authors.forename: Vu D
authors.initials: VD
authors.lastname: Thiem
authors.forename: Rick
authors.initials: R
authors.lastname: Rheingans
authors.forename: Le H
authors.initials: le H
authors.lastname: Tho
authors.forename: Roger I
authors.initials: RI
authors.lastname: Glass
authors.forename: Joseph S
authors.initials: JS
authors.lastname: Bresee
mesh_terms: D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003967:Diarrhea / Q000191:economics* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D017048:Health Care Costs; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000191:economics*; D016896:Treatment Outcome; D014611:Vaccination / Q000191:economics; D014744:Vietnam
chemical_list: D022243:Rotavirus Vaccines